Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
In a step likely to advance personalized cancer treatment, scientists have for the first time shown in patients that levels of biomarkers are not enough to tell which patients are likely to respond best to immunotherapy.
A recent study from Cornell University offers a new perspective on how the chemotherapy agent etoposide delays and kills vital enzymes that support the growth of cancer cells.
On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein.
The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.
Researchers at the University of Waterloo have created a computational model to predict the growth of deadly brain tumors more accurately.
Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.
The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.
Due to the continuous cellular activity, malfunctions frequently occur, making error-correcting systems crucial for cells. However, it serves the cancer cells’ best interests to cause errors when it comes to destroying them.
CTCF is a critical protein known to play various roles in key biological processes such as transcription.
Most cells have a pretty normal life: they're born, they grow, they get old, and they die. But the Benjamin Buttons of the cellular world can go from old to young again in the right context.
A tool was developed by researchers to forecast the impact of various dietary plans on both cancerous and healthy cells.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Groundbreaking research has revealed the secret of how plants tend to make limonoids, a family of useful organic chemicals which incorporate bee-friendly insecticides and have the potential as anti-cancer drugs.
The first simple production of customizable proteins known as zinc fingers to treat diseases by turning genes on and off might be enabled with the help of an artificial intelligence (AI) program.
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.
Researchers from Nagoya University’s Graduate School of Medicine in Japan have uncovered how microRNA (miRNA) affects inflammation in mice with lupus. They discovered two downregulated miRNAs in the disease along with a rare circumstance where several miRNAs control the same set of genes.
By using artificial human skin, a research group from the University of Copenhagen have managed to block invasive growth in a skin cancer model.
Researchers from the University of Cambridge have described a new DNA sequencing technique that can find out where and how small molecule drugs interact with the targeted genome in a study that was published in the journal Nature Biotechnology.
The protein SPOP, which also plays a role in endometrial, uterine, and other cancers, is the most mutated in prostate cancer. Despite its significance, it is still unclear how SPOP mutations cause cancer.